You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):上海澤潤在北京設立全資子公司 投建重組新型冠狀病毒疫苗(CHO細胞)產業化項目
格隆匯 08-27 22:04

格隆匯8月27日丨沃森生物(300142.SZ)公佈,2021年8月26日,公司第四屆董事會第二十七次會議審議通過了《關於上海澤潤生物科技有限公司設立全資子公司並投資建設在研產品產業化項目的議案》。

董事會同意控股子公司上海澤潤生物科技有限公司在北京市大興區設立其全資子公司北京澤潤創新生物技術有限公司(暫定名,最終名稱以工商行政管理機關核准的名稱為準,簡稱“北京澤潤”),註冊資本為5.2億元,並以北京澤潤為投資主體投資建設重組新型冠狀病毒疫苗(CHO細胞)產業化項目。

項目計劃依託公司的全資子公司北京沃森創新生物技術有限公司(簡稱“北京沃森”)在北京沃森大興疫苗產業園正在建設的2號疫苗生產車間及相關配套設施實施產業化,計劃總投資5.2億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account